Medicine and Dentistry
COVID-19
100%
Dyspnea
70%
Major Depressive Episode
57%
Treatment Resistant Depression
46%
Randomized Controlled Trial
37%
Post-COVID-19
36%
Prospective Cohort Study
35%
Single Drug Dose
33%
Minocycline
33%
Mental Health
33%
Psilocybine
33%
Systematic Review
33%
Network Meta-Analysis
33%
Cohort Analysis
33%
Lung
33%
Depressive Disorder
33%
Sleep Disorder
33%
Sleep Quality
30%
Montgomery-Åsberg Depression Rating Scale
26%
Acute Disease
16%
Comorbidity
16%
Diseases
14%
Cognitive Defect
12%
UK Biobank
12%
Arm
11%
Anti-Inflammatory Drug
11%
Actigraphy
9%
Numeric Rating Scale
9%
Pittsburgh Sleep Quality Index
9%
Generalized Anxiety Disorder
8%
middle age
8%
Cluster Analysis
8%
Clinician
7%
Body Mass Index
7%
Adverse Event
6%
Least Square Analysis
6%
Severe Depression
6%
Dizziness
6%
Automutilation
6%
Headache
6%
Nausea
6%
Rating Scale
6%
Adverse Effect
6%
Logistic Regression Analysis
6%
Deterioration
6%
Muscle Weakness
6%
Mood Disorder
5%
Patient Health Questionnaire 9
5%
Hamilton Rating Scale for Depression
5%
Placebo
5%
Nursing and Health Professions
Dyspnea
75%
Prospective Cohort Study
37%
Quality of Life
33%
Cross-Sectional Study
33%
Patient with Congestive Heart Failure
33%
Alcohol Consumption
33%
Minocycline
33%
Network Meta-Analysis
33%
Cohort Analysis
33%
Acute Disease
33%
Sleep Disorder
33%
Comorbidity
33%
Treatment Resistant Depression
33%
Mental Health
33%
Sleep Quality
33%
Systematic Review
33%
Cognitive Defect
25%
Depressive Disorder
22%
Prevalence
20%
Cluster Analysis
16%
Biobank
13%
Diseases
12%
Logistic Regression Analysis
12%
Congestive Heart Failure
11%
Longitudinal Analysis
11%
Beck Depression Inventory
11%
Center for Epidemiological Studies Depression Scale
11%
Actimetry
10%
Pittsburgh Sleep Quality Index
10%
Numeric Rating Scale
10%
Body Mass
8%
C Reactive Protein
8%
Artificial Respiration
8%
Major Depression
7%
Hospital Discharge
6%
Muscle Weakness
6%
Deterioration
6%
Public Hospital
5%
Physical Disease
5%
Heart Disease
5%
Mortality Rate
5%
Tetracycline
5%
Pharmacology, Toxicology and Pharmaceutical Science
Major Depression
70%
Treatment Resistant Depression
46%
Randomized Controlled Trial
46%
Depressive Disorder
38%
Mood Disorder
38%
Inflammation
33%
Prospective Cohort Study
33%
Acute Disease
33%
Comorbidity
33%
Minocycline
33%
Psilocybin
33%
Cognitive Defect
25%
Placebo
23%
N Methyl Dextro Aspartic Acid
22%
Remission
20%
Bipolar Disorder
20%
Diseases
15%
Immunomodulating Agent
13%
Anti-Inflammatory Drug
11%
Dysthymia
8%
C Reactive Protein
8%
Dyspnea
8%
Adverse Event
6%
Nausea
6%
Clinical Trial
6%
Automutilation
6%
Headache
6%
Dizziness
6%
Monotherapy
6%
Mood Stabilizer
5%
Glutamate Decarboxylase
5%
Generalized Anxiety Disorder
5%
Pathophysiology
5%
Side Effect
5%
Ketamine
5%
DSM-IV
5%
Pharmacotherapy
5%
Tetracycline
5%
Biological Marker
5%
Cytokine
5%
